EVT Stock Overview
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Evotec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €13.77 |
| 52 Week High | €24.16 |
| 52 Week Low | €12.68 |
| Beta | 1.11 |
| 1 Month Change | 8.60% |
| 3 Month Change | -9.82% |
| 1 Year Change | -27.75% |
| 3 Year Change | -59.01% |
| 5 Year Change | -36.98% |
| Change since IPO | -25.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| EVT | AT Life Sciences | AT Market | |
|---|---|---|---|
| 7D | -5.1% | -3.2% | -0.08% |
| 1Y | -27.8% | -9.5% | 3.0% |
Return vs Industry: EVT underperformed the Austrian Life Sciences industry which returned -9.5% over the past year.
Return vs Market: EVT underperformed the Austrian Market which returned 3% over the past year.
Price Volatility
| EVT volatility | |
|---|---|
| EVT Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in AT Market | 5.3% |
| 10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: EVT's share price has been volatile over the past 3 months.
Volatility Over Time: EVT's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 5,086 | Mario Polywka | www.evotec.com |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women’s health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019.
Evotec SE Fundamentals Summary
| EVT fundamental statistics | |
|---|---|
| Market cap | €2.44b |
| Earnings (TTM) | -€94.98m |
| Revenue (TTM) | €820.80m |
3.0x
P/S Ratio-25.7x
P/E RatioIs EVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVT income statement (TTM) | |
|---|---|
| Revenue | €820.80m |
| Cost of Revenue | €600.96m |
| Gross Profit | €219.84m |
| Other Expenses | €314.82m |
| Earnings | -€94.98m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 24, 2024
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 26.78% |
| Net Profit Margin | -11.57% |
| Debt/Equity Ratio | 51.6% |
How did EVT perform over the long term?
See historical performance and comparison